RedHill Biopharma announced yesterday that the FDA has approved Talicia for the treatment of H. pylori infection in adults. The label is broad and potentially positions Talicia to compete as a front-line treatment. Talicia now is the only rifabutin-based combination antibiotic treatment approved by the FDA. In two Phase III clinical trials conducted by RedHill, no resistance to rifabutin was observed, which will be the key competitive advantage compared to standard-of-care clarithromycin-base
05 Nov 2019
RedHill Biopharma - FDA approves Talicia for H. pylori
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
RedHill Biopharma - FDA approves Talicia for H. pylori
- Published:
05 Nov 2019 -
Author:
Dr Jonas Peciulis -
Pages:
2
RedHill Biopharma announced yesterday that the FDA has approved Talicia for the treatment of H. pylori infection in adults. The label is broad and potentially positions Talicia to compete as a front-line treatment. Talicia now is the only rifabutin-based combination antibiotic treatment approved by the FDA. In two Phase III clinical trials conducted by RedHill, no resistance to rifabutin was observed, which will be the key competitive advantage compared to standard-of-care clarithromycin-base